[go: up one dir, main page]

PE20090982A1 - Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) - Google Patents

Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)

Info

Publication number
PE20090982A1
PE20090982A1 PE2008001884A PE2008001884A PE20090982A1 PE 20090982 A1 PE20090982 A1 PE 20090982A1 PE 2008001884 A PE2008001884 A PE 2008001884A PE 2008001884 A PE2008001884 A PE 2008001884A PE 20090982 A1 PE20090982 A1 PE 20090982A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
cetp
cholesteryl
inhibitors
Prior art date
Application number
PE2008001884A
Other languages
English (en)
Inventor
Muneto Mogi
Ken Yamada
Kayo Yasoshima
Toshio Kawanami
Ichiro Umemura
Yuki Iwaki
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40343337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090982(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20090982A1 publication Critical patent/PE20090982A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIPERIDINA DE FORMULA (I) DONDE R1 ES CICLOALQUILO, ARILO, ALQUILO, ENTRE OTROS; R2 ES ALQUILO, CICLOALQUILO, ALCOXILO, ENTRE OTROS; R3 ES HOC(O)-R9-C(O)- O HOC(O)-R9-O-C(O)-, EN DONDE R9 ES ALQUILO, ALQUIL-CICLOALQUIL, ARILO, ENTRE OTROS; R4 Y R5 SON CADA UNO H, ALQUILO, ALCOXILO, CICLOALQUILO, ARILO, ENTRE OTROS; R6 Y R7 SON CADA UNO H, ALQUILO, HALO-ALQUILO, HALOGENO, CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-CARBAMOIL-BUTIL-ESTER DEL ACIDO CIS-4-{[3,5-BIS-(TRIFLUORO-METIL)-BENCIL]-[5-(1-METIL-1H-PIRAZOL-4-IL)-PIRIMIDIN-2-IL]-AMINO}-2,6-DIETIL-PIPERIDIN-1-CARBOXILICO, TERBUTIL-ESTER DEL ACIDO CIS-2-BENCIL-4-[(3,5-BIS-(TRIFLUORO-METIL)-BENCIL)-(5-MORFOLIN-4-IL-PIRIMIDIN-2-IL)-AMINO]-6-ETIL-PIPERIDIN-1-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA DE TRANSFERENCIA DE COLESTERIL-ESTER (CETP) SIENDO UTILES EN EL TRATAMIENTO DE HIPERLIPIDEMIA, ATEROSCLEROSIS, ENFERMEDAD CARDIACA CORONARIA
PE2008001884A 2007-11-05 2008-11-03 Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) PE20090982A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98545607P 2007-11-05 2007-11-05

Publications (1)

Publication Number Publication Date
PE20090982A1 true PE20090982A1 (es) 2009-08-13

Family

ID=40343337

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001884A PE20090982A1 (es) 2007-11-05 2008-11-03 Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)

Country Status (24)

Country Link
US (3) US8193349B2 (es)
EP (2) EP2207775B1 (es)
JP (1) JP5555635B2 (es)
KR (1) KR101564793B1 (es)
CN (1) CN101910150B (es)
AR (1) AR069165A1 (es)
AT (1) ATE550333T1 (es)
AU (1) AU2008324243B2 (es)
BR (1) BRPI0819223A2 (es)
CA (1) CA2704633C (es)
CL (1) CL2008003284A1 (es)
CY (1) CY1112706T1 (es)
DK (1) DK2207775T3 (es)
EA (1) EA022912B1 (es)
ES (2) ES2381518T3 (es)
HR (1) HRP20120476T1 (es)
JO (1) JO2732B1 (es)
MX (1) MX2010004929A (es)
PE (1) PE20090982A1 (es)
PL (2) PL2207775T3 (es)
PT (2) PT2207775E (es)
SI (1) SI2207775T1 (es)
TW (1) TWI426910B (es)
WO (1) WO2009059943A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2404901B1 (en) 2007-12-03 2013-05-22 Novartis AG 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
SI3141252T1 (sl) 2009-06-17 2018-12-31 Vertex Pharmaceuticals Incorporated Inhibitorji replikacije virusov influence
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
EP2646444B1 (en) 2010-12-03 2016-03-16 Epizyme, Inc. Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes
EP2668507B1 (en) 2011-01-26 2017-08-23 INSERM - Institut National de la Santé et de la Recherche Médicale Method for assessing a subject's risk of having a cardiovascular disease.
ES2804528T3 (es) * 2011-07-05 2021-02-08 Vertex Pharma Procesos y productos intermedios para la producción de azaindoles
KR20190025737A (ko) * 2011-07-08 2019-03-11 노파르티스 아게 높은 트리글리세리드 대상체에서의 아테롬성동맥경화증의 치료 방법
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
AU2012339722B2 (en) 2011-11-14 2017-09-14 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A
BR112014029295B1 (pt) * 2012-05-25 2021-04-27 Nutech Ventures Ciclobutenos e ciclobutanos anfifílicos e composição farmacêutica que os compreende
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
TN2016000031A1 (en) 2013-07-25 2017-07-05 Novartis Ag Cyclic polypeptides for the treatment of heart failure
TW201518323A (zh) 2013-07-25 2015-05-16 Novartis Ag 合成ａｐｅｌｉｎ多肽之生物結合物
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
PL3068782T3 (pl) 2013-11-13 2018-12-31 Vertex Pharmaceuticals Incorporated Sposoby wytwarzania inhibitorów replikacji wirusów grypy
PE20171328A1 (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media
CN104788482B (zh) * 2015-01-23 2016-09-14 沧州普瑞东方科技有限公司 一种制备2-氨基嘧啶-5-硼酸频那醇酯的方法
CA2982810A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN111787981A (zh) 2018-03-01 2020-10-16 瑞泽恩制药公司 改变身体组成的方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
TW313568B (es) 1994-12-20 1997-08-21 Hoffmann La Roche
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
DK1115693T3 (da) 1998-09-25 2007-07-23 Monsanto Co Substituerede polycykliske aryl- og heteroaryl-Si(tertiære)-heteroalkylaminer der er egnede til inhibering af cholesteryl-esther-transferproteinaktivitet
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
US6583183B2 (en) * 1999-09-23 2003-06-24 Pharmacia Corporation Substituted n-phenyl-n-fused-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
WO2001098344A2 (en) 2000-06-16 2001-12-27 Curis, Inc. Angiogenesis-modulating compositions and uses
GB0021885D0 (en) 2000-09-06 2000-10-18 Fujisawa Pharmaceutical Co New use
US7109204B2 (en) 2001-08-01 2006-09-19 Merck & Co., Inc. Tyrosine kinase inhibitors
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
EP1553075B1 (en) 2002-10-03 2013-08-14 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
JPWO2004101529A1 (ja) * 2003-05-19 2006-07-13 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
JP2007507481A (ja) * 2003-09-30 2007-03-29 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害薬及びその代謝産物
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
JP2007530550A (ja) 2004-03-26 2007-11-01 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物および方法
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
MY139887A (en) * 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
US20060270675A1 (en) * 2005-03-10 2006-11-30 Groneberg Robert D Inhibitors of cholesterol ester transfer protein
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
JP4258499B2 (ja) * 2005-07-25 2009-04-30 ヤマハ株式会社 吹奏電子楽器の音源制御装置とプログラム
US20070203183A1 (en) 2006-01-13 2007-08-30 Schering Corporation Diaryl piperidines as CB1 modulators
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
WO2007107843A1 (en) 2006-03-22 2007-09-27 Pfizer Products Inc. Methods of treatment with cetp inhibitors
UY30244A1 (es) * 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
JP5042311B2 (ja) * 2006-07-20 2012-10-03 ノバルティス アーゲー Ｃｅｔｐ阻害剤としてのアミノピペリジン誘導体
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
JP4846769B2 (ja) 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
EP2404901B1 (en) 2007-12-03 2013-05-22 Novartis AG 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
PL2231636T3 (pl) 2007-12-07 2012-04-30 Novartis Ag Pochodne pirazolowe i ich zastosowanie jako inhibitorów kinaz zależnych od cyklin

Also Published As

Publication number Publication date
TWI426910B (zh) 2014-02-21
KR20100094986A (ko) 2010-08-27
PL2207775T3 (pl) 2012-08-31
MX2010004929A (es) 2010-05-27
US8193349B2 (en) 2012-06-05
PT2463282E (pt) 2013-11-11
ES2381518T3 (es) 2012-05-29
HK1168096A1 (en) 2012-12-21
CA2704633A1 (en) 2009-05-14
PT2207775E (pt) 2012-05-11
US8440682B2 (en) 2013-05-14
US20120208816A1 (en) 2012-08-16
TW200924779A (en) 2009-06-16
CA2704633C (en) 2015-10-20
US20090118287A1 (en) 2009-05-07
EA022912B1 (ru) 2016-03-31
WO2009059943A1 (en) 2009-05-14
DK2207775T3 (da) 2012-06-18
EP2207775A1 (en) 2010-07-21
CN101910150A (zh) 2010-12-08
ES2434417T3 (es) 2013-12-16
CN101910150B (zh) 2013-09-18
AU2008324243A1 (en) 2009-05-14
KR101564793B1 (ko) 2015-10-30
AR069165A1 (es) 2010-01-06
US8420641B2 (en) 2013-04-16
JP2011503026A (ja) 2011-01-27
JP5555635B2 (ja) 2014-07-23
EP2463282B1 (en) 2013-08-07
AU2008324243B2 (en) 2012-03-08
PL2463282T3 (pl) 2014-01-31
EA201000750A1 (ru) 2010-12-30
CY1112706T1 (el) 2016-02-10
BRPI0819223A2 (pt) 2020-08-18
HRP20120476T1 (hr) 2012-06-30
CL2008003284A1 (es) 2009-05-15
SI2207775T1 (sl) 2012-05-31
US20120264773A1 (en) 2012-10-18
EP2207775B1 (en) 2012-03-21
JO2732B1 (en) 2013-09-15
ATE550333T1 (de) 2012-04-15
EP2463282A1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
PE20090982A1 (es) Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
PE20120632A1 (es) Inhibidores de bace
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20130242A1 (es) Derivados de isoxazolo-piridina
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20080772A1 (es) Nuevos derivados de bipiridina sustituidos y su uso
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
PE20091000A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
PE20110404A1 (es) Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de la orexina
PE20141375A1 (es) Activadores de glucoquinasa
PE20121158A1 (es) Derivados de feniletinilo como moduladores alostericos positivos (map)
PE20110419A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
PE20061096A1 (es) Derivados de oxiindol como agonistas 5-ht4
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
PE20141529A1 (es) Derivados de biciclo [3,2,1] octilamida y sus usos
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
PE20070528A1 (es) Compuestos heterociclicos como ligandos del receptor vaniloide del subtipo 1
PE20080345A1 (es) Derivados de piperazina como agonistas del receptor de gpr38
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20070076A1 (es) Aminopirimidinas como moduladores de quinasas
PE20091527A1 (es) Derivados de piridazinona

Legal Events

Date Code Title Description
FG Grant, registration